Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic responseAmir Fathi, Yi‐Bin Chen, Katherine M. Edmonds et al.|Blood|2012Cited by 123
Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemiaAmir T. Fathi, Yi‐Bin Chen, Seth A. Wander et al.|Haematologica|2016Cited by 43
PD-1 inhibition in advanced myeloproliferative neoplasmsGabriela Hobbs, John Mascarenhas, Cansu Cimen Bozkus et al.|Blood Advances|2021Cited by 43
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutationAmir T. Fathi, Mark J. Levis, Traci M. Blonquist et al.|Cancer|2017Cited by 31
Prospective evaluation of serial 2-hydroxyglutarate in acute myeloid leukemia (AML) to determine response to therapy and predict relapse.Amir T. Fathi, Richard M. Stone, Omar Abdel‐Wahab et al.|Journal of Clinical Oncology|2012Cited by 0